Persons with dispensed medicines; origin
| Sex | Age | Origin | Medicine group (ATC) | Periods | Persons with medicines, relative (%) | Defined daily doses (DDD), relative (number per 1 000 persons) |
|---|---|---|---|---|---|---|
| Total male and female | Total age | Total | Total | 2023* | 64.01 | 480,027 |
| Total male and female | Total age | Total | A Alimentary tract and metabolism | 2023* | 21.61 | 86,436 |
| Total male and female | Total age | Total | A01 Stomatological preparations | 2023* | 0.55 | 34 |
| Total male and female | Total age | Total | A01A Stomatological preparations | 2023* | 0.55 | 34 |
| Total male and female | Total age | Total | A02 Drugs for acid related disorders | 2023* | 12.22 | 44,171 |
| Total male and female | Total age | Total | A02A Antacids | 2023* | 0.00 | 1 |
| Total male and female | Total age | Total | A02B Drugs for peptic ulcer and gord | 2023* | 12.22 | 44,171 |
| Total male and female | Total age | Total | A02X Oth. drugs for acid related disord. | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A03 Drugs for funct.gastrointest.disord. | 2023* | 2.01 | 1,203 |
| Total male and female | Total age | Total | A03A Drugs for functional bowel disord. | 2023* | 0.47 | 919 |
| Total male and female | Total age | Total | A03B Belladonna and derivatives, plain | 2023* | 0.02 | 2 |
| Total male and female | Total age | Total | A03C Antispasmodics with psycholeptics | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A03D Antispasmodics with analgesics | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A03E Antispasmodics and anticholinergics | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A03F Propulsives | 2023* | 1.57 | 282 |
| Total male and female | Total age | Total | A04 Antiemetics and antinauseants | 2023* | 0.74 | 71 |
| Total male and female | Total age | Total | A04A Antiemetics and antinauseants | 2023* | 0.74 | 71 |
| Total male and female | Total age | Total | A05 Bile and liver therapy | 2023* | 0.10 | 286 |
| Total male and female | Total age | Total | A05A Bile therapy | 2023* | 0.10 | 286 |
| Total male and female | Total age | Total | A05B Liver therapy, lipotropics | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A05C Bile therapy drugs and lipotropics | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A06 Laxatives | 2023* | 8.56 | 5,906 |
| Total male and female | Total age | Total | A06A Laxatives | 2023* | 8.56 | 5,906 |
| Total male and female | Total age | Total | A07 Anti diarr/intest/infl/infect.agents | 2023* | 1.03 | 3,842 |
| Total male and female | Total age | Total | A07A Intestinal antiinfectives | 2023* | 0.43 | 83 |
| Total male and female | Total age | Total | A07B Intestinal adsorbents | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A07C Electrolytes with carbohydrates | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A07D Antipropulsives | 2023* | 0.12 | 113 |
| Total male and female | Total age | Total | A07E Intestinal antiinflammatory agents | 2023* | 0.50 | 3,646 |
| Total male and female | Total age | Total | A07F Antidiarrheal microorganisms | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A07X Other antidiarrheals | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A08 Antiobesity prep. excl.diet products | 2023* | 0.01 | 12 |
| Total male and female | Total age | Total | A08A Antiobesity prep.excl.diet products | 2023* | 0.01 | 12 |
| Total male and female | Total age | Total | A09 Digestives, incl. enzymes | 2023* | 0.12 | 366 |
| Total male and female | Total age | Total | A09A Digestives, incl. enzymes | 2023* | 0.12 | 366 |
| Total male and female | Total age | Total | A10 Drugs used in diabetes | 2023* | 5.04 | 30,097 |
| Total male and female | Total age | Total | A10A Insulins and analogues | 2023* | 1.51 | 7,614 |
| Total male and female | Total age | Total | A10B Blood glucose lowering drugs, excl. | 2023* | 4.48 | 22,484 |
| Total male and female | Total age | Total | A10X Other drugs used in diabetes | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A11 Vitamins | 2023* | 0.17 | 249 |
| Total male and female | Total age | Total | A11A Multivitamins, combinations | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A11B Multivitamins, plain | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A11C Vit A and D, incl.combin.of the two | 2023* | 0.17 | 243 |
| Total male and female | Total age | Total | A11D Vitamin B1,and with vit. B6 and B12 | 2023* | 0.01 | 3 |
| Total male and female | Total age | Total | A11E Vitamin B-complex, incl. combinat. | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A11G Ascorbic acid (vitamin C) + combin. | 2023* | 0.00 | 3 |
| Total male and female | Total age | Total | A11H Other plain vitamin preparations | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A11J Other vitamin products + combinat. | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A12 Mineral supplements | 2023* | 0.19 | 156 |
| Total male and female | Total age | Total | A12A Calcium | 2023* | 0.00 | 1 |
| Total male and female | Total age | Total | A12B Potassium | 2023* | 0.15 | 126 |
| Total male and female | Total age | Total | A12C Other mineral supplements | 2023* | 0.04 | 30 |
| Total male and female | Total age | Total | A13 Tonics | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A13A Tonics | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A14 Anabolic agents for systemic use | 2023* | 0.00 | 2 |
| Total male and female | Total age | Total | A14A Anabolic steroids | 2023* | 0.00 | 2 |
| Total male and female | Total age | Total | A14B Other anabolic agents | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A15 Appetite stimulants | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | A16 Other aliment.tract/metabol.products | 2023* | 0.01 | 40 |
| Total male and female | Total age | Total | A16A Oth.aliment.tract and metabol.prod. | 2023* | 0.01 | 40 |
| Total male and female | Total age | Total | B Blood and blood forming organs | 2023* | 13.33 | 50,408 |
| Total male and female | Total age | Total | B01 Antithrombotic agents | 2023* | 10.72 | 32,753 |
| Total male and female | Total age | Total | B01A Antithrombotic agents | 2023* | 10.72 | 32,753 |
| Total male and female | Total age | Total | B02 Antihemorrhagics | 2023* | 0.32 | 79 |
| Total male and female | Total age | Total | B02A Antifibrinolytics | 2023* | 0.25 | 48 |
| Total male and female | Total age | Total | B02B Vitamin k and other hemostatics | 2023* | 0.07 | 31 |
| Total male and female | Total age | Total | B03 Antianemic preparations | 2023* | 3.36 | 17,571 |
| Total male and female | Total age | Total | B03A Iron preparations | 2023* | 1.90 | 575 |
| Total male and female | Total age | Total | B03B Vitamin B12 and folic acid | 2023* | 1.63 | 16,996 |
| Total male and female | Total age | Total | B03X Other antianemic preparations | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | B05 Blood substitutes / perfus.solutions | 2023* | 0.28 | 4 |
| Total male and female | Total age | Total | B05A Blood and related products | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | B05B Intravenous solutions | 2023* | 0.27 | 4 |
| Total male and female | Total age | Total | B05C Irrigating solutions | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | B05D Peritoneal dialytics | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | B05X Intravenous solution additives | 2023* | 0.02 | 0 |
| Total male and female | Total age | Total | B05Z Hemodialytics and hemofiltrates | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | B06 Other hematological agents | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | B06A Other hematological agents | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | C Cardiovascular system | 2023* | 21.31 | 164,497 |
| Total male and female | Total age | Total | C01 Cardiac therapy | 2023* | 2.45 | 5,024 |
| Total male and female | Total age | Total | C01A Cardiac glycosides | 2023* | 0.45 | 649 |
| Total male and female | Total age | Total | C01B Antiarrhythmics, class I and III | 2023* | 0.39 | 885 |
| Total male and female | Total age | Total | C01C Cardiac stimulants excl. glycosides | 2023* | 0.32 | 5 |
| Total male and female | Total age | Total | C01D Vasodilators used in card. diseases | 2023* | 1.36 | 3,299 |
| Total male and female | Total age | Total | C01E Other cardiac preparations | 2023* | 0.07 | 186 |
| Total male and female | Total age | Total | C02 Antihypertensives | 2023* | 0.34 | 1,124 |
| Total male and female | Total age | Total | C02A Antiadren.agents, centrally acting | 2023* | 0.09 | 108 |
| Total male and female | Total age | Total | C02B Antiadren.agents, ganglion-blocking | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | C02C Antiadren.agents, peripher. acting | 2023* | 0.24 | 980 |
| Total male and female | Total age | Total | C02D Arteriolar smooth muscle agents | 2023* | 0.00 | 3 |
| Total male and female | Total age | Total | C02K Other antihypertensives | 2023* | 0.01 | 33 |
| Total male and female | Total age | Total | C02L Antihypertensives/diuretics combin. | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | C02N Combinations of antihypertensives.. | 2023* | 0.00 | 0 |
| Total male and female | Total age | Total | C03 Diuretics | 2023* | 5.67 | 14,822 |
| Total male and female | Total age | Total | C03A Low-ceiling diuretics, thiazides | 2023* | 3.04 | 6,008 |
| Total male and female | Total age | Total | C03B Low-ceiling diuret.,excl. thiazides | 2023* | 0.33 | 701 |
| Total male and female | Total age | Total | C03C High-ceiling diuretics | 2023* | 1.93 | 6,553 |
| Total male and female | Total age | Total | C03D Potassium-sparing agents | 2023* | 1.23 | 1,374 |
| Total male and female | Total age | Total | C03E Diuretics/potassium-sparing agents | 2023* | 0.06 | 185 |
| Source: CBS. | ||||||
Table explanation
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. Also, the number of dispensed defined daily doses (DDDs) are presented. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Basic Registration of Persons (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
Data are broken down by medicine group, origin, age and sex.
Data available from 2020
Status of the figures:
Figures for 2022 are provisional, figures for previous years are final.
Changes as of December 18, 2024:
- Provisional figures for 2023 have been added, provisional figures of 2022 have been made definite.
When will new figures be published?
New figures will be published in the last quarter of 2025.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.
- Defined daily doses (DDD), relative
- Defined Daily Dose (DDD) is the WHO-determined assumed average maintenance dose per day for a drug used for its main indication in adults. This fixed unit of measurement makes it possible to compare the use of different forms of administration, package sizes and strengths.
WHO: World Health Organisation, World Health Organisation